Acquisition, Equity-Method Investment and Licensing Arrangements (Tables)

9 Months Ended

Sep. 27, 2020

Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]

Equity Method Investment

Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the three and nine months ending June 30, 2020, the most recent period available, is as follows:
(MILLIONS OF DOLLARS)	June 30, 2020
Current assets	$	7,136
Noncurrent assets	37,108
Total assets	$	44,244
Current liabilities	$	4,992
Noncurrent liabilities	5,195
Total liabilities	$	10,187
Equity attributable to shareholders	$	33,919
Equity attributable to noncontrolling interests	138
Total net equity	$	34,057

(MILLIONS OF DOLLARS)	Three Months Ended June 30, 2020		Nine Months Ended June 30, 2020
Net sales	$	2,927	$	9,618
Cost of sales	(1,061)		(4,266)
Gross profit	$	1,866	$	5,352
Income from continuing operations	524		995
Net income	524		995
Income attributable to shareholders	518		959